Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Carcinoma × Dasatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Leukemia, Myeloid, Chronic-Phase 7 Recurrence 5 Leukemia, Lymphocytic, Chronic, B-Cell 5 Breast Neoplasms 5 Multiple Myeloma 4 Leukemia, Myeloid, Acute 4 Burkitt Lymphoma 4 Waldenstrom Macroglobulinemia 3 Prostatic Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Extranodal NK-T-Cell 3 Lung Neoplasms 3 Leukemia, Myeloid, Accelerated Phase 3 Leukemia 3 Immunoblastic Lymphadenopathy 3 Hodgkin Disease 3 Squamous Cell Carcinoma of Head and Neck 2 Sezary Syndrome 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Myelodysplastic Syndromes 2 Mycosis Fungoides 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, T-Cell, Cutaneous 2

Interventions

Carboplatin 6 pembrolizumab 4 Sorafenib 3 Pemetrexed 3 Paclitaxel 3 Gemcitabine 3 Cyclophosphamide 3 seocalcitol 2 selinexor 2 patritumab 2 osimertinib 2 liposomal doxorubicin 2 interferon gamma-1b 2 fludarabine 2 Sunitinib 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Irinotecan 2 Interleukin-2 2 Erlotinib Hydrochloride 2 DNA 2 Cisplatin 2 Celecoxib 2 Capecitabine 2 Bleomycin 2 Albumin-Bound Paclitaxel 2 130-nm albumin-bound paclitaxel 2 volociximab 1 thioredoxin reductase inhibitor AM12 1 sonidegib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00564876 2015-02-23

TOP0706

Duke University

Phase 2 Terminated

2 enrolled 4 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡